ArticleBiochemistry and biophysics reports2026
Comparative proteomics of human naso-oropharyngeal swabs from COVID19 patients for identification of potential biomarker candidates.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID19 continues to be a public health issue with subvariants of the main strains causing infections globally. This study looks to identify potential biomarker candidates that can help to understand molecular etio-pathogenesis. Proteins from naso-oropharyngeal samples of healthy Control and COVID19 subjects were trypsin digested and subjected to liquid chromatography assisted mass spectrometry analysis on Orbitrap Fusion Lumos (ThermoFisher). Proteomic analysis was carried out using Proteome Discoverer 2.4 (ThermoFisher) using human and SARS-CoV-2 FASTA databases from UniProtKB. Proteins with fold Change ≤0.5, or ≥2 were designated as differentially expressed and taken up for interactomic analysis using STRING and Cytoscape, and pathway analysis using KEGG, Reactome, and Wiki pathway. Area under curve for receiver operating characteristic was done in MetaboAnalyst (v6.0) to estimate diagnostic parameters of sensitivity and specificity. Proteomic analysis of naso-oropharyngeal swabs from COVID19 patients identified 26 differentially expressed human proteins of which 11 are potential biomarker candidate proteins. In addition, 29 SARS-CoV-2 specific peptides from spike protein, nucleocapsid, membrane, ORF1ab, ORF6, ORF7a, ORF8 and ORF9b proteins have been identified of which 6 were mutated. These SARS-CoV-2 proteins make an array of interactions with the identified human proteins establishing their roles in pathogenesis of viral infection. Human biomarker candidate proteins are associated with alterations in glycolytic pathways and immune dysregulation, which are known to facilitate viral invasion, replication, and contribute to disease severity. Identified biomarker candidates have a minimum of 70% and a maximum of 100%, sensitivity and specificity thereby having translational value in developing protein-based tests that can complement currently available diagnostics for COVID19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.